We are:

  • Clinical Stage Biotechnology Company Specializing in Human Vaccines
  • Creating, Developing, Manufacturing & Testing Innovative HIV/AIDS Vaccines
  • Conducting Multiple Site Phase 1 HIV/AIDS Human Clinical Vaccine Trials

Our AIDS Vaccines:

  • Are Designed for Predominant AIDS Virus Subtypes
  • Use DNA & Viral Vector Technologies
  • Demonstrated Excellent Preclinical Data: 96% Protection in Non-Human Primates
  • Completed Satisfactory Phase 1 Human Trial
  • DNA & MVA Human Trials Stimulating Immune Responses

Our Business:

  • Vaccines: The Most Cost Effective Way to Combat Infectious Disease
  • Large Global AIDS Vaccine Market = >$4 Billion
  • Customers: Humans - All Ages, Sexes, Races, Nationalities, Geographical Regions
  • People with AIDS in 2006 is estimated at 39.5 Million

19 May 2008

Shot in the Dark - Forbes Magazine

Read full story (pdf) »

12 May 2008

$10 Million Financing Commitment Secured

Read full story (pdf) »

08 May 2008

HIV Drug Tests Set for Phase 2 - Atlanta Journal Constitution

Read full story (pdf) »

24 March 2008

McNally Joins GeoVax Team

Read full story (pdf) »

GeoVax Company Fact Sheet

View pdf »

Current Job Openings

View all »